Matthew M Halpert earned his B.S. (Biology/Chemistry) with high honors at Southwestern University (Georgetown, TX) from 2002-2006 and then proceeded directly into a doctoral tract at the University of Alabama-Birmingham, where he was a member of the inaugural HHMI-Health to Med Program (with a focus on translating science to the clinic). Dr. Halpert quickly earned his PhD in 2011 from the Department of Microbiology with a focus on Immunology. Following a brief stint as a postdoctoral fellow at Baylor College of Medicine (Houston, Tx) he accepted a faculty position at BCM, a top medical institution tucked away in the largest medical center in the world (Houston, Tx). Within his research lab over the past decade, the team has focused on studying basic immunological processes, homeostatic regulation, and cancer immunotherapy, the latter of which lead to Dr. Halpert co-founding Diakonos Research Ltd in 2015, an early stage cancer immunotherapy company. With collaborators (e.g. BCM, MD Anderson, Cooper Hospital, Texas Heart Institute, St. Lukes, etc.) Diakonos is on the precipice of numerous FDA-approved phase I clinical trials for the treatment of multiple types of advanced cancer utilizing novel, strong, well-studied science within his lab, as well as several international licensing deals for said science. In addition to his roles with BCM and Diakonos, in 2018 Dr. Halpert accepted a position as the director of R&D for Medterra CBD, and is responsible for the scientific directions of Medterra and of all CBD product related research, development, and innovation. He currently has over 30 peer reviewed publications, is listed on 9 patents, holds several consulting positions, and has given countless presentations and interviews. In 2020, numerous groups from the NIH solicited his advice and input for ways to improve scientific structures and advancements regarding both ‘cancer cell therapies’ and ‘alternative immune regulators’ such as CBD, and international groups have sought his guidance pertaining to offering cutting-edge cancer immunotherapy to applicable patients in need today.